Cardiff Oncology CRDF shares were trading higher on Thursday after the company highlighted its presentation of its data at the ESMO confirming its efficacy of the Onvansertib and durability in response to KRAS-Mutated metastatic colorectal cancer.
Cardiff Oncology is a clinical-stage company with the singular mission of developing new treatment options for cancer patients. Its objective is to overcome resistance, extend duration of response and increase overall survival.
Cardiff Oncology shares were up 49% at $8.70 at the time of publication on Thursday. The stock has a 52-week high of $11.18 and a 52-week low of 70 cents.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
